Cita APA

A, E., A, G., A, L., JF, B., I, G., F, S., . . . R, M. (2023). Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer.

Citación estilo Chicago

A, Estepa-Fernández, García-Fernández A, Lérida-Viso A, Blandez JF, Galiana I, Sancenon-Galarza F, Orzáez M, y Martínez-Máñez R. Combination of Palbociclib With Navitoclax Based-therapies Enhances in Vivo Antitumoral Activity in Triple-negative Breast Cancer. 2023.

Cita MLA

A, Estepa-Fernández, et al. Combination of Palbociclib With Navitoclax Based-therapies Enhances in Vivo Antitumoral Activity in Triple-negative Breast Cancer. 2023.